Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-066401
Filing Date
2025-05-08
Accepted
2025-05-08 07:42:48
Documents
58
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nuvl-20250331.htm   iXBRL 10-Q 2229287
2 EX-31.1 nuvl-ex31_1.htm EX-31.1 17910
3 EX-31.2 nuvl-ex31_2.htm EX-31.2 17919
4 EX-32.1 nuvl-ex32_1.htm EX-32.1 10871
5 EX-32.2 nuvl-ex32_2.htm EX-32.2 9401
6 GRAPHIC img241476914_0.jpg GRAPHIC 173738
  Complete submission text file 0000950170-25-066401.txt   7595236

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nuvl-20250331.xsd EX-101.SCH 844512
61 EXTRACTED XBRL INSTANCE DOCUMENT nuvl-20250331_htm.xml XML 1130672
Mailing Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 508-446-2272
Nuvalent, Inc. (Filer) CIK: 0001861560 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40671 | Film No.: 25923936
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)